# OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

> **NCT00471432** · PHASE1 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 40 (actual)

## Conditions studied

- Bladder Cancer
- Breast Cancer
- Kidney Cancer
- Lung Cancer
- Ovarian Cancer
- Prostate Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** custirsen sodium
- **DRUG:** docetaxel
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00471432
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04-04
- **Primary completion:** 2006-03-09
- **Final completion:** 2009-12-21
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471432, "OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00471432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*